Based on these findings, it is suggested that CHRNB2 may regulate the malignant phenotype of colorectal cancer by modulating downstream signaling cascades, including the PI3K–AKT–mTOR and β-catenin pathways. This evidence concerns the gene MTOR and colorectal cancer.